Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ACBP

ACBP

Basics

Aliases:
This biomarker is also known as:
  • endozepine,
  • Acyl-Coenzyme A Binding Domain Containing 1,
  • Endozepine,
  • diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein),
  • DBI,
  • Diazepam-Binding Inhibitor,
  • ACBD1,
  • CCK-RP,
  • EP,
  • Cholecystokinin-Releasing Peptide, Trypsin-Sensitive,
  • GABA Receptor Modulator,
  • Acyl-CoA-Binding Protein,

View in BioMuta

Description…

DBI, diazepam binding inhibitor, was previously known as ACBP, acyl-coA binding protein. This protein is regulated by hormones, is involved in lipid metabolism, and is thought to act as a neuropeptide to regulate the action of the GABA receptor. DBI is conserved across species. The most highly conserved domain is the hydrophobic binding site for medium- and long-chain acyl-coA esters. DBI is involved in the regulation of pancreatic secretion and release of cholecystokinin. There are three pseudogenes for DBI on separate chromosomes. DBI has multiple transcript variants encoding different isoforms.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: DBI

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Under Review

Overview

The role of ACBP, also known as DBI, in lung tumorigenesis is unknown. ACBP plays a role in lipid metabolism and acts as acyl-CoA transporter and intracellular pool former. In spite of the fact that ACBP is ubiquitously expressed (29), its differential expression in normal epithelium and invasive tissues was clearly demonstrated by MALDI MS. To our knowledge, this is the first report of overexpression of ACBP in lung tumorigenesis.

Performance Comment

ACBP, also known as DBI, belongs to a 9-member panel that provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions. The identified members of the panel are TMSB4X (Thymosin beta-4), Ubiquitin, des-ubiquitin, ACBP, CSTA, Cytochrome C, and MIF.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.

Announcement